Was the Barry Ticho Stoke Therapeutics (STOK) share sale under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sale was executed under a Rule 10b5-1 trading plan adopted by Barry Ticho on November 19, 2025 . Such pre-arranged plans schedule trades in advance, helping separate routine diversification from discretionary timing decisions.

Stoke Therapeutics (STOK) CMO sells 2,243 shares in open-market trade

Q: What insider transaction did Stoke Therapeutics (STOK) report for Barry Ticho?

Stoke Therapeutics reported that chief medical officer Barry Ticho sold 2,243 shares of common stock in an open-market transaction on May 1, 2026 . This was a routine Form 4 filing reflecting a single sale of non-derivative common stock.

Q: At what price did Barry Ticho sell Stoke Therapeutics (STOK) shares?

Barry Ticho sold 2,243 shares of Stoke Therapeutics common stock at an average price of $32.79 per share . The filing characterizes the transaction as an open-market sale , meaning the shares were sold through normal market trading rather than a private block transaction.

Q: How many Stoke Therapeutics (STOK) shares does Barry Ticho hold after the sale?

After the reported transaction, Barry Ticho directly holds 36,621 shares of Stoke Therapeutics common stock. This post-transaction holding figure in the Form 4 helps show that the sale represents only a portion of his overall direct equity position in the company.

Q: What type of security did Barry Ticho sell in Stoke Therapeutics (STOK)?

The filing shows Barry Ticho sold Common Stock of Stoke Therapeutics in a non-derivative transaction. No options, warrants, or other derivatives were involved, and the derivativeSummary section of the data is empty, indicating no derivative trades reported in this Form 4.

Q: How is the Barry Ticho Stoke Therapeutics (STOK) transaction coded on Form 4?

The transaction is coded as “S” , described as a sale in open market or private transaction . The normalized data classifies it as an open-market sale with a sell direction, distinguishing it from grants, option exercises, gifts, or tax-withholding entries.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported an open-market sale of company stock. On May 1, 2026, he sold 2,243 shares of common stock at $32.79 per share. Following this transaction, he directly holds 36,621 shares of Stoke Therapeutics common stock.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Barry Ticho adopted on November 19, 2025. Such plans are designed to allow insiders to sell shares according to a preset schedule, helping separate routine portfolio management from discretionary trading decisions.

Insider Trade Summary 10b5-1

Net Seller: 2,243 shares ($73,548)

Net Sell 1 txn

Insider Ticho Barry

Role CHIEF MEDICAL OFFICER

Sold 2,243 shs ($74K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,243	$32.79	$74K

Holdings After Transaction: Common Stock — 36,621 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 2,243 shares Sale price per share: $32.79 per share Shares held after transaction: 36,621 shares +1 more

4 metrics

Shares sold 2,243 shares Open-market sale of common stock on May 1, 2026

Sale price per share $32.79 per share Average price for the 2,243 shares sold

Shares held after transaction 36,621 shares Direct common stock ownership following the sale

Transaction code S Classified as sale in open market or private transaction

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/05/2026 - 04:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last)

(First)

(Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD

MASSACHUSETTS

01730

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		S⁽¹⁾		2,243	D	$32.79	36,621	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

	/s/ Jonathan Allan, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for Barry Ticho?

Stoke Therapeutics reported that chief medical officer Barry Ticho sold 2,243 shares of common stock in an open-market transaction on May 1, 2026. This was a routine Form 4 filing reflecting a single sale of non-derivative common stock.

At what price did Barry Ticho sell Stoke Therapeutics (STOK) shares?

Barry Ticho sold 2,243 shares of Stoke Therapeutics common stock at an average price of $32.79 per share. The filing characterizes the transaction as an open-market sale, meaning the shares were sold through normal market trading rather than a private block transaction.

How many Stoke Therapeutics (STOK) shares does Barry Ticho hold after the sale?

After the reported transaction, Barry Ticho directly holds 36,621 shares of Stoke Therapeutics common stock. This post-transaction holding figure in the Form 4 helps show that the sale represents only a portion of his overall direct equity position in the company.

What type of security did Barry Ticho sell in Stoke Therapeutics (STOK)?

The filing shows Barry Ticho sold Common Stock of Stoke Therapeutics in a non-derivative transaction. No options, warrants, or other derivatives were involved, and the derivativeSummary section of the data is empty, indicating no derivative trades reported in this Form 4.

How is the Barry Ticho Stoke Therapeutics (STOK) transaction coded on Form 4?

The transaction is coded as “S”, described as a sale in open market or private transaction. The normalized data classifies it as an open-market sale with a sell direction, distinguishing it from grants, option exercises, gifts, or tax-withholding entries.